Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 2/20 | 0.34 |
| ▸ | NOS3 | P29474 | 1/20 | 0.34 |
| ▸ | NOS2 | P35228 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL29940301 | 0.98 | NOS1 (0.33) | NOS1NOS3NOS2 | |
| SCHEMBL4312543 | 0.86 | SLC6A1 (0.33) | NOS1NOS3NOS2 | |
| SCHEMBL7383261 | 0.86 | SLC6A1 (0.33) | NOS1NOS3NOS2 | |
| SCHEMBL7390438 | 0.86 | SLC6A1 (0.33) | NOS1NOS3NOS2 | |
| SCHEMBL4641765 | 0.85 | NOS1 (0.31) | NOS1NOS3NOS2 | |
| SCHEMBL1919959 | 0.84 | CPN1 (0.41) | NOS2 | |
| SCHEMBL20594016 | 0.84 | CPN1 (0.41) | NOS2 | |
| SCHEMBL20594008 | 0.84 | CPN1 (0.41) | NOS2 | |
| SCHEMBL31564804 | 0.82 | DPP4 (0.36) | NOS1NOS3NOS2 | |
| SCHEMBL14978004 | 0.82 | DPP4 (0.36) | NOS1NOS3NOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115557929-A | Somatostatin modulators and uses thereof | 克林提克斯医药股份有限公司 | 2023-01-03 | — | — | CN | disclosed |
| CN-109715612-B | Somatostatin modulators and uses thereof | 克林提克斯医药股份有限公司 | 2022-09-16 | — | — | CN | disclosed |
| CN-107043366-A | 4 amino-metadiazine compounds, its preparation method and medical usage | 中国药科大学 | 2017-08-15 | — | — | CN | disclosed |
| EP-1981892-B1 | THIENO-PYRIDINE DERIVATIVES AS MEK INHIBITORS | UCB PHARMA SA (BE) | 2014-03-12 | — | — | EP | disclosed |
| US-8604051-B2 | Thieno-pyridine derivatives as MEK inhibitors | UCB PHARMA S.A. (BE) | 2013-12-10 | — | — | US | disclosed |
| CN-101622243-B | Sulfonamide derivative | ASAHI KASEI PHARMA CORP | 2013-12-04 | — | — | CN | disclosed |
| US-20130150573-A1 | THIENO-PYRIDINE DERIVATIVES AS MEK INHIBITORS | UCB PHARMA S.A. (BE) | 2013-06-13 | — | — | US | disclosed |
| US-8394822-B2 | Thieno-pyridine derivatives as MEK inhibitors | UCB PHARMA, S.A. (BE) | 2013-03-12 | — | — | US | disclosed |
| US-20120329774-A1 | THIENO-PYRIDINE DERIVATIVES AS MEK INHIBITORS | UCB PHARMA S.A. (BE) | 2012-12-27 | — | — | US | disclosed |
| US-8283359-B2 | Thieno-pyridine derivatives as MEK inhibitors | UCB PHARMA S.A. (BE) | 2012-10-09 | — | — | US | disclosed |
| EP-2130828-A1 | SULFONAMIDE DERIVATIVE | Asahi Kasei Pharma Corporation (JP) | 2009-12-09 | — | — | EP | disclosed |
| US-20090149437-A1 | THIENO-PYRIDINE DERIVATIVES AS MEK INHIBITORS | UCB PHARMA S.A. (BE) | 2009-06-11 | — | — | US | disclosed |
| CN-101379067-A | Thieno-pyridine derivatives as MEK inhibitors | UCB PHARMA SA (BE) | 2009-03-04 | — | — | CN | disclosed |
| US-20090048223-A1 | Sulfonamide compound | ASAHI KASEI PHARMA CORPORATION (JP) | 2009-02-19 | — | — | US | disclosed |
| EP-1981892-A1 | THIENO-PYRIDINE DERIVATIVES AS MEK INHIBITORS | UCB Pharma, S.A. (BE) | 2008-10-22 | — | — | EP | disclosed |
| WO-2007088345-A1 | THIENO-PYRIDINE DERIVATIVES AS MEK INHIBITORS | UCB PHARMA S.A. (BE) | 2007-08-09 | — | — | WO | disclosed |
| EP-0871628-A1 | QUINOLIZINONE TYPE COMPOUNDS | Abbott Laboratories (US) | 1998-10-21 | — | — | EP | disclosed |
| US-5726182-A | TREATMENT OF BACTERIAL INFECTIONS | ABBOTT LABORATORIES (US) | 1998-03-10 | — | — | US | disclosed |
| US-5599816-A | BACTERICIDE | ABBOTT LABORATORIES (US) | 1997-02-04 | — | — | US | disclosed |
| WO-1996039407-A1 | QUINOLIZINONE TYPE COMPOUNDS | ABBOTT LABORATORIES (US) | 1996-12-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120329774-A1 | THIENO-PYRIDINE DERIVATIVES AS MEK INHIBITORS | MAP3K6, MAPK1, MAP3K20 | NOS1 1205/4885NOS3 1193/4885NOS2 1159/4885 |
| US-20090149437-A1 | THIENO-PYRIDINE DERIVATIVES AS MEK INHIBITORS | MAP3K6, MAPK1, MAP3K20 | NOS1 1205/4885NOS3 1193/4885NOS2 1159/4885 |
| US-20090048223-A1 | Sulfonamide compound | ALK, AKT1, ARAF | NOS1 673/4885NOS3 504/4885NOS2 644/4885 |
| US-20130150573-A1 | THIENO-PYRIDINE DERIVATIVES AS MEK INHIBITORS | MAP2K2, MAPK1, MAP3K6 | NOS1 897/4885NOS3 1071/4885NOS2 1067/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.